Phenformin and ataxia‐telangiectasia mutated inhibitors synergistically co‐suppress liver cancer cell growth by damaging mitochondria

Phenformin and ataxia‐telangiectasia mutated inhibitors synergistically co‐suppress liver cancer cell growth by damaging mitochondria

Inhibitors of ataxia–telangiectasia mutated (ATM), such as KU‐55933 (Ku), represent a promising class of novel anticancer drugs. In addition, the biguanide derivative phenformin exhibits antitumor activity superior to that of the AMPK activator metformin. Herein, we assessed the potential combinator...

Full description

Bibliographic Details
Main Authors: Tianyu Wu, Sichun Zhou, Mei Qin, Jing Tang, Xinjian Yan, Lingli Huang, Meiyuan Huang, Jun Deng, Di Xiao, Xin Hu, Jingtao Wu, Xiaoping Yang, Gaofeng Li
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:FEBS Open Bio
Subjects:
KU‐55933
liver cancer
mitochondria
p‐AMPK
phenformin
Online Access:https://doi.org/10.1002/2211-5463.13152

Internet

https://doi.org/10.1002/2211-5463.13152

Similar Items